Ayrmid has not obtained the necessary financing to support its unsolicited, nonbinding written proposal to purchase the company, Bluebird said.

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder ...

US gene therapy company bluebird bio (Nasdaq: BLUE) announced that after three weeks of engagement, including a timeline ...

Bluebird (Nasdaq: BLUE) said its board unanimously recommended going forward with the acquisition offer from Carlyle and SK ...

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing ...

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. | After striking ...

Bluebird bio announced that despite extending the timeline for Ayrmid to complete due diligence and submit a binding offer, Ayrmid failed to meet these conditions. Mark Vachon, chairman of Bluebird’s ...

The Philippine Heart Center has reached a significant milestone by successfully performing six Transcatheter Aortic Valve ...

In a move to accelerate global access to sustainable vivarium solutions, Innovive, LLC has partnered with EAD Scientific, LLC to expand distribution across Latin America and the Caribbean (LAC).

Bluebird Bio (BLUE) announced that after three weeks of engagement, including a timeline extension, Ayrmid has not submitted a binding proposal ...

SOMERVILLE, Mass., April 16, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd.